- Home
- IOTR vs BNR Comparison
IOTR vs BNR Comparison
Compare IOTR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOTR
- BNR
- Stock Information
- Founded
- IOTR 2019
- BNR 2014
- Country
- IOTR Singapore
- BNR China
- Employees
- IOTR N/A
- BNR N/A
- Industry
- IOTR
- BNR Medical Specialities
- Sector
- IOTR
- BNR Health Care
- Exchange
- IOTR NYSE
- BNR Nasdaq
- Market Cap
- IOTR 29.5M
- BNR 38.3M
- IPO Year
- IOTR 2025
- BNR 2020
- Fundamental
- Price
- IOTR $0.48
- BNR $4.63
- Analyst Decision
- IOTR
- BNR
- Analyst Count
- IOTR 0
- BNR 0
- Target Price
- IOTR N/A
- BNR N/A
- AVG Volume (30 Days)
- IOTR 327.6K
- BNR 20.0K
- Earning Date
- IOTR 01-01-0001
- BNR 08-21-2025
- Dividend Yield
- IOTR N/A
- BNR N/A
- EPS Growth
- IOTR N/A
- BNR N/A
- EPS
- IOTR N/A
- BNR N/A
- Revenue
- IOTR $10,478,550.00
- BNR $72,112,038.00
- Revenue This Year
- IOTR N/A
- BNR $136.32
- Revenue Next Year
- IOTR N/A
- BNR N/A
- P/E Ratio
- IOTR N/A
- BNR N/A
- Revenue Growth
- IOTR 22.27
- BNR 0.53
- 52 Week Low
- IOTR $0.31
- BNR $2.18
- 52 Week High
- IOTR $5.98
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- IOTR N/A
- BNR 73.56
- Support Level
- IOTR N/A
- BNR $3.06
- Resistance Level
- IOTR N/A
- BNR $3.50
- Average True Range (ATR)
- IOTR 0.00
- BNR 0.24
- MACD
- IOTR 0.00
- BNR 0.11
- Stochastic Oscillator
- IOTR 0.00
- BNR 82.64
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.